HKG:9887

3 stories mentioning HKG:9887Updated 32d ago

Every FINWIRES story that references HKG:9887, newest first.

Nanjing Leads Biolabs Trustee to Buy Up to $50 Million in Shares Under Award Scheme; Shares Up 4%

Nanjing Leads Biolabs (HKG:9887) said its trustee will acquire up to $50 million of the company's H-shares through on-market transactions under its H-share award scheme, according to a Wednesday Hong Kong bourse filing.Shares of the biotech company were up nearly 4% in Thursday morning trade.The purchased shares will be used for future share awards to eligible participants, subject to vesting conditions under the scheme.Leads Biolabs said the share purchases are intended to enhance flexibility in compensation arrangements and help attract and retain talent.

HKG:9887

Asia34d ago

Nanjing Leads Biolabs Wins China Approval for Phase 3 Neuroendocrine Cancer Trial

Nanjing Leads Biolabs (HKG:9887) received approval from China's National Medical Products Administration to commence a Phase 3 clinical study of LBL-024 for advanced extrapulmonary neuroendocrine carcinoma, according to a Tuesday Hong Kong bourse filing.The study will evaluate LBL-024, a PD-L1/4-1BB bispecific antibody, in combination with platinum-based chemotherapy as a first-line treatment for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).

HKG:9887

Asia62d ago

Nanjing Leads Biolabs Enrolls First Patient in Phase 2 Study of Gastric Cancer Drug

Nanjing Leads Biolabs (HKG:9887) said it enrolled the first patient in the phase 2 clinical study of its cancer drug LBL-024, according to a Hong Kong bourse filing Tuesday.The firm will evaluate the drug, which is also known as Opamtistomig, for the treatment of first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

HKG:9887

Track with the FINWIRES app suite

FolioX

Track HKG:9887 in your portfolio

WheelAI

Analyze HKG:9887 options with the wheel strategy

StockInsider

See market sentiment on HKG:9887